Albireo Pharma (ALBO -0.9%) completes the enrollment of 47 subjects in a Phase 2 clinical trial
evaluating ileal bile acid transporter (IBAT) elobixibat (5 mg) in
patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic
steatohepatitis (NASH), the first such study assessing an IBAT inhibitor
in these patients according to the company.
The primary endpoint is the change from baseline in low-density lipoprotein cholesterol (“bad” cholesterol) at week 16.
Topline data should be available mid-year.
https://seekingalpha.com/news/3550162-albireo-advancing-mid-stage-study-of-ibat-inhibitor-in-nash-nafld
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.